Nightingale Health Plc | Stock Exchange Release | October 02, 2025 at 09:00:00 EEST
Nightingale Health Plc’s Annual Report for financial year 1 July 2024–30 June 2025 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report.
The Annual Report is attached to this release, and is also available on Nightingale Health’s website https://ir.nightingalehealth.com/financial-reports. The Corporate Governance Statement will be available also at https://ir.nightingalehealth.com/corporate-governance-statements, and the Remuneration Report at https://ir.nightingalehealth.com/remuneration-reports.
Nightingale Health Plc publishes the financial statements also in XHTML format in accordance with the European Single Electronic Format (ESEF) reporting requirements. In line with the ESEF requirements, the primary statements in the consolidated financial statements have been labelled with XBRL tags. Notes to financial statements have been labelled with XBRL block tags. The audit firm PricewaterhouseCoopers Oy has provided an independent auditor’s reasonable assurance report on Nightingale Health’s ESEF Financial Statements in accordance with ISAE 3000 (Revised). The ESEF financial statements in Finnish are available in the zip file attached to this release and at https://ir.nightingalehealth.com/financial-reports.
For further information, please contact
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
At Nightingale Health, we believe there is a way to make healthcare better for everyone. We can reduce costs for payers and ease the burden on healthcare professionals while helping people live long and healthy lives. This is possible by introducing a healthcare logic built on prevention, where the aim is to reduce the number of sick people. That is why we have created the Nightingale Health Check. With every blood sample, we make better healthcare possible for everyone.
Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/
Image Attachments
Nightingale Health
